Skip to main content

Forge Biologics expands, releases 'amazing' results in infants treated with its gene therapy

Revenue grew by "multiples" in 2022, its second full year of biotech manufacturing, and a "large jump" is projected for this year, executives said. The startup is on a path to profitability.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.